| abstract |
Methods are provided for treating hereditary hemorrhagic telangiectasia and related diseases by the administration of linifanib, Ki8751, cediranib, foretinib, AEE788, SAR412988, ponatinib, analogs or derivatives thereof, a pharmaceutically acceptable salt or ester of the foregoing, or combinations thereof. Methods are also provided for treating diseases associated with mutations in the activin A receptor like type 1 (ACVRL1) gene, the SMAD family member 4 (SMAD4) gene, and/or the endoglin (ENG) gene. |